首頁 > 市場調查報告書 > 製藥

臨床實驗

市場調查報告書

商品編碼

1140743

全球動靜脈瘺市場-2022-2029

Global Arteriovenous Fistula Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

對先進治療的需求不斷增長

在預測期內，隨著參與者開發新的療法，如光動力療法、血管生成療法和其他硬化療法，預計動靜脈瘺護理市場將擴大。以簡單的方式實現完全康復的成功治療形式仍在開發中，促使玩家提出創新的治療技術。此外，增加 FDA 對用於動靜脈瘺形成的非侵入性設備的批准推動了預測期內的市場增長。

此外，眾所周知，血液透析的最佳途徑是自製動靜脈瘺。另一方面，外科動靜脈瘺的構建是技術能力差的代名詞，可能需要多個程序來幫助成熟和保持初始通暢。經常有。由於這些缺點，目前正在研究許多可以改善手術程序和性能的新方法。正在研究製造新的微創系統的方法，並取得了初步成果。此外，研究管道中大量治療藥物的存在和樂觀的政府政策預計將在預測期內改善對動靜脈瘺的需求。

市場發展是由改進的治療方法驅動的，例如血管生成、光動力療法和輔助形式的硬化療法。為這種疾病的全面治療制定適當的治療計劃是一個持續且困難的過程。這就產生了對行業領導者提出的新技術和改進處理工藝的需求。市場發展因對該疾病的低認識而受到阻礙。

然而，缺乏能夠解決動靜脈瘺具體原因的有效治療劑將限制市場的擴大。恢復通常需要比預期更長的時間或訪問不成熟。此外，需要一根針來進入動靜脈瘺進行透析。

地理滲透。

北美地區有望主導全球動靜脈瘺市場

該研究按地區分析了全球市場的動靜脈瘺市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

在地理上，由於美國政府積極主動地為動靜脈瘺疾病開發新的治療藥物，北美在全球動靜脈瘺市場處於領先地位。歐洲動靜脈瘺市場是僅次於美國的第二大市場。歐洲動靜脈瘺市場的增長主要是由於該地區動靜脈瘺發病率的增加以及對動靜脈瘺治療的旺盛需求。

此外，亞太國家因其先進的醫學水平，被定位為世界動靜脈瘺的發展中國家。

競爭格局。

由於美國、中國和印度等關鍵地區的主要市場參與者的存在，動靜脈瘺市場保持適度競爭。對全球市場增長做出貢獻的主要動靜脈瘺製造商包括 Pervasis Therapeutics, Inc.、Proteon Therapeutics, Inc.、Medtronic、Cook Medical、Fresenius Medical Care AG &Co.KGaA、Poly Medicure Limited、Becton Dickinson and Company、Braun Melsungen Ag , Teleflex 公司等領先公司正在為全球動靜脈瘺市場的增長採用新產品推出和擴張戰略。2020年9月，全球醫療技術領導者美敦力收購了私營醫療器械公司Avenue Medical。Avenue的經皮瘺管技術增強了medtronic的外周通路產品組合，並強化了medtronic改善終末期腎病患者預後的承諾。2020 年 9 月，medtronic通過收購 Avenu Medical 擴大了其透析通路的地位。該公司將收購 Avenu Medical，該公司生產一種系統，可為需要建立透析通路的終末期腎病患者創建微創動靜脈 (AV) 瘺管。2020 年 1 月，Cook Medical 和 Bentley 宣布了一項臨床試驗合作戰略，涉及 Cook 的柵欄和分支支架移植物以及 Bentley 的覆膜支架。

COVID-19 的影響。對全球動靜脈瘺市場的負面影響。

全球醫療保健系統正受到最近被稱為 2020 年冠狀病毒病 (COVID-19) 的流行病的挑戰。到 4 月初，已有超過 100 萬例陽性病例登記，51,737 人死亡。在大流行期間，維持醫療基礎設施的全球解決方案至關重要。推遲選擇性治療的最大理由是讓衛生系統為大流行做好準備。關於是否應該推遲血管手術以及護理 COVID-19 患者所需的安全措施，已經提出了各種問題。此外，血液透析的血管通路被認為是患者的生命線，其維護對於護理的一致性至關重要。巴西腎髒病學會跟隨其他受 COVID-19 流行影響的國家的組織的腳步，為醫療保健機構制定了這些建議，強調了實施程序以規劃和保護血管通路的價值。我詳細解釋了。非選擇性治療以及從非隧道式導管到發病率較低的隧道式導管的過渡是血液透析、移植物和動靜脈瘺的關鍵通路發展。

全球動靜脈瘺市場報告提供對大約 53 個市場數據表、40 個數字和 170 頁的訪問。

Pervasis Therapeutics, Inc.
- 公司簡介
- 產品組合和描述
- 主要亮點
- 財務摘要
Proteon Therapeutics, Inc.
Medtronic,
Cook Medical
Fresenius Medical Care AG & Co. KGaA
Poly Medicure Limited
Becton Dickinson and Company
Braun Melsungen Ag
Teleflex Incorporated
NxStage Medical, Inc.（*LIST NOT EXHAUSTIVE）

第 12 章重要注意事項

第 13 章數據管理

簡介目錄

Product Code: DMPH3137

Market Overview

Arteriovenous Fistula Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Sub-Domain: Others

The interruption of blood supply caused by an irregular link between a vein and an artery is known as an arteriovenous fistula. Blood passes straight from lungs to veins in the event of an arteriovenous fistula, bypassing capillaries. Capillary tissues thus obtain smaller supplies of oxygen (blood supply) and raise the risk of complications with blood pressure. Fistulas between the arteries and veins may be congenital or inherited. Congenital fistula occurs during embryonic development and mainly affects blood vessels in the lower extremities. While acquired fistula typically happens when veins and arteries are impaired, the healing process results in two parallel vein and artery connections. Further, the arteriovenous fistula is formed on the arms, kidneys, brain, or certain parts of the legs. Penetrating damage, arterial vein breakup, and inflammatory necrosis of adjacent veins all increase the risk of an arteriovenous fistula. With consistent efforts of key players to develop novel therapeutics for the treatment of arteriovenous fistula, the global arteriovenous fistula market is seeing fast growth in the forecast period.

Market Dynamics: Growing demand for advanced treatment methods

Over the projected period, the arteriovenous fistulas care market is expected to expand as players develop new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. The successful form of therapy for a complete recovery in a simple way is still in the development process, which inspires players to come up with innovative treatment technologies. Further, growing FDA approvals for noninvasive devices for arteriovenous fistula creation have resulted in the market growth over the forecast period.

Moreover, the optimal access for hemodialysis transmission is known to be an autogenous arteriovenous fistula. On the other hand, the surgical development of an arteriovenous fistula is synonymous with less-than-ideal technical performance, and numerous procedures are often required to aid maturation or preserve early patency. With these deficiencies, many new methods are now under study that can enhance surgical procedures and/or performance. Minimally invasive new system manufacturing methods are being studied, with early research findings available. Furthermore, the presence of a vast number of therapeutics in the research pipeline and optimistic government policies would improve the demand for arteriovenous fistula over the forecast period.

Market players are improving their treatment approaches, such as antiangiogenic therapy, photodynamic therapy and an additional form of sclerotherapy, as factors contributing to this development. Developing an appropriate therapeutic plan for the full treatment of the condition is a challenging process still in progress. It generated the need for new technologies and improvements in the treatment process for industry leaders to come up with. The market's development is hampered by a lack of awareness about the disease.

However, the lack of effective therapeutics that can address the particular cause of arteriovenous fistula, the other hand, would restrict the market's expansion. Often recovery may take longer than expected, or access can fail to mature. Further, to access the AV fistula for dialysis, needles are required.

Market Segmentation: The radial cephalic fistula segment is projected to be the dominant segment in the market during the forecast period.

Based on the type, the arteriovenous fistula market has been classified into the radial cephalic fistula, brachial cephalic, brachial basilic transposition.

As part of the Kidney disease outcomes quality initiative (KDOQI), the 2006 recommendations suggested by the National Kidney Foundation suggest that a radiocephalic fistula be the first alternative for fistula creation. This is because the radiocephalic fistula has a lower rate of steal syndrome than upper arm fistulas and because developing this forearm fistula retains the possibility of creating a more proximal fistula in the future if this access fails. The maturation rate for radiocephalic fistulas, however, is low, with one analysis finding that up to two-thirds of radiocephalic fistulas have not matured.

The global arteriovenous fistula market is segmented based on treatment methods, which includes endovascular embolization, microsurgery, stereotactic radiosurgery.

The endovascular embolization segment is expected to account for a significant market share in the Arteriovenous Fistula market. Endovascular embolization is a recent therapeutic procedure for arteriovenous malformations (AVM). During this procedure, a catheter is implanted through the groin into the arteries in the brain that contribute to the AVM, and material is injected into the arteries. This injection blocks the artery, limiting blood flow into the AVM. Usually, endovascular embolization alone does not remove the AVM and is, thus, almost exclusively used as a preliminary step in either microsurgical resection or stereotactic radiotherapy preparation.

Geographical Penetration: North America region is expected to dominate the global Arteriovenous Fistula market

Based on geography, the study analyzes the arteriovenous fistula market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Geographically, owing to positive measures by the U.S. government to create new therapeutics for arteriovenous fistula disease, North America leads the worldwide arteriovenous fistula market. Europe is the second-largest market for arteriovenous fistulas after the U.S. The growth of this market in Europe is mainly due to the growing occurrence of arteriovenous fistula in this region, combined with a strong demand for arteriovenous fistula therapy.

Moreover, owing to the growing healthcare understanding among the patient population, Asia-Pacific countries are the developing countries in the worldwide arteriovenous fistula industry.

Competitive Landscape:

The arteriovenous fistula market is moderately competitive, owing to the presence of major market players in key regions such as the US, China, India and others. The key arteriovenous fistula players which are contributing to the growth of the global market include Pervasis Therapeutics, Inc., Proteon Therapeutics, Inc., Medtronic, Cook Medical, Fresenius Medical Care AG & Co. KGaA, Poly Medicure Limited, Becton Dickinson and Company, Braun Melsungen Ag, Teleflex Incorporated among others. The major players are adopting new product launches and expansion strategies for global growth in the arteriovenous fistula market. In September 2020, Medtronic, the global leader in medical technology, acquired Avenue Medical, a privately held medical device company. Avenu's Percutaneous Fistula Creation Technology strengthens the Medtronic Peripheral Vascular Access Portfolio and Reinforces Medtronic's Commitment to Improving Outcomes for Patients with End-Stage Renal Disease. In September 2020, Medtronic expanded its dialysis access position with Avenu Medical buyout. The company plans to acquire Avenu Medical, which produces a system for minimally invasive creation of arteriovenous (AV) fistulae for end-stage renal disease patients who need to establish dialysis access. In January 2020, Cook Medical and Bentley announced their collaboration strategy for a clinical trial involving Cook's fenestrated and branch stent grafts and Bentley's covered stents.

COVID-19 Impact: Negative impact on the global arteriovenous fistula market.

The global healthcare system has been challenged by a recent epidemic known as coronavirus disease 2020 (COVID-19). More than 1,000,000 positive cases had been registered by the beginning of April, with 51,737 deaths. A global solution to sustain the healthcare infrastructure is crucial during a pandemic. The primary justification for delaying elective treatments is ensuring the healthcare system can keep up with the pandemic. There have been various questions about whether to postpone vascular operations and the safety steps needed to care for a patient with COVID-19. Moreover, hemodialysis vascular accesses are considered the patient's lifeline, and their upkeep is vital for care consistency. The Brazilian Society of Nephrology developed these recommendations for healthcare facilities, elaborating on the value of conducting procedures for the planning and protection of vascular accesses, following the lead of organizations in other countries affected by the COVID-19 pandemic. Non-elective treatments, as well as the transition from the use of non-tunnel catheters to tunnel catheters causing less morbidity, are the development of conclusive accesses for hemodialysis, grafts and arteriovenous fistulas.

The global arteriovenous fistula market report would provide an access to approximately 53 market data tables, 40 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Treatment Methods
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing demand for advanced treatment methods
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of effective therapeutics
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
- 7.3.1. Radial Cephalic fistula
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Brachial Cephalic
- 7.3.3. Brachial Basilic Transposition

8. By Treatment Methods

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods Segment
8.3. Market Attractiveness Index, By Treatment Methods Segment
- 8.3.1. Endovascular embolization
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Microsurgery
- 8.3.3. Stereotactic radiosurgery

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Global Arteriovenous Fistula Market- Company Profiles

11.1. Pervasis Therapeutics, Inc.
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Proteon Therapeutics, Inc.
11.3. Medtronic,
11.4. Cook Medical
11.5. Fresenius Medical Care AG & Co. KGaA
11.6. Poly Medicure Limited
11.7. Becton Dickinson and Company
11.8. Braun Melsungen Ag
11.9. Teleflex Incorporated
11.10. NxStage Medical, Inc.(*LIST NOT EXHAUSTIVE)